India approves its first dengue vaccine QDENGA after DCGI clearance
India has officially approved the QDENGA dengue vaccine, developed by Takeda Biopharmaceuticals, for individuals aged 4 to 60. The vaccine does not require pre-screening for past infections and is designed to protect against all four dengue virus serotypes.
Why it matters
This approval is a significant public health milestone for India, which faces a high burden of dengue cases annually.
NEW DELHI: India has approved its first dengue vaccine, with the Drug Controller General of India (DCGI) granting market authorisation to vaccine QDENGA, developed by Takeda Biopharmaceuticals India. The vaccine is approved for people aged 4 to 60 years and can be given regardless of whether a person has previously been infected with dengue.Unlike some dengue vaccines, QDENGA does not require pre-vaccination screening, allowing eligible individuals to receive the vaccine without first being tested for past dengue infection.Takeda said the approval marks a major step in India's fight against dengue, a mosquito-borne disease that affects millions of people every year."Since its launch in 2022, QDENGA has been approved in 43 countries, with more than 32 million doses distributed globally.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in